TCR2 Therapeutics: Rises on positive data from ovarian cancer therapy study

TCR2 Therapeutics

14/12/2020 12:12

** Biotech co's  TCRR.O  shares rise 2.3% to $33.4 premarket
    ** Co on Sunday reported positive interim data from its
ongoing early-stage trial of TC-210 in patients with advanced
solid tumors, including ovarian cancer  urn:newsml:reuters.com:*:nGNXbsLHcc
    ** TC-210 induced tumor regression in all of the first eight
patients, including in first ovarian cancer patient 
    ** Co amends Phase 1 trial to  enable faster
dose-escalation, after encouraging safety data 
    ** Brokerage H.C. Wainwright raises PT to $37 from $32 on
increased probability of TC-210's approval in ovarian cancer 
    ** Brokerage Jefferies raises PT to $39 from $33
    ** Says co has over four months of follow-up, and believes
the data update continues to show a positive trend
    ** TCRR stock up ~129% this year, as of last close

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))